Clinical Trials Logo

Clinical Trial Summary

Thyroid ophthalmopathy, also known as thyroid eye disease or Graves' ophthalmopathy, is a condition characterized by inflammation and swelling of the tissues around the eyes, often accompanied by protrusion of the eyeballs. This condition can lead to significant discomfort, visual disturbances, and in severe cases, permanent vision loss. Primary treatment modalities are intravenous methylprednisolone (IVMP) and other medications for patients with moderate to severe and active thyroid eye disease. In addition, external beam radiation therapy (ERT) is an another treatment option in combination with IVMP. Radiation therapy delivers targeted doses of ionizing radiation to the affected orbital tissues, effectively reducing inflammation. This approach is particularly beneficial for patients who may not respond adequately to steroid therapy alone or those who experience recurrent disease flares. This study will test the efficacy of a shortened treatment regimen comprising 5 sessions of ERT to a standard protocol of 10 treatments. The primary aim is to ascertain the effectiveness of shorted radiation treatment while improving patients' quality of life.


Clinical Trial Description

The research methodology of this study involves comparing the standard protocol of 10 radiation treatments with a modified approach comprising 5 treatments of daily External Beam Radiation Therapy (ERT). The primary objective of this investigation is to assess whether reducing the number of radiation treatments while maintaining the effectiveness of the therapy can lead to improvements in the quality of life for patients with thyroid ophthalmopathy. By comparing these two treatment regimens, researchers aim to evaluate the efficacy and safety of the abbreviated radiation schedule in managing the symptoms and progression of the disease. Participants enrolled in the study will be randomized into two groups: one receiving the standard 10 treatments and the other receiving the modified 5-treatment regimen of daily ERT. Throughout the study period, participants will undergo comprehensive assessments to monitor changes in symptoms, vision, and quality of life. These evaluations will include ophthalmic examinations, imaging studies, and patient-reported outcome measures to capture both objective and subjective measures of treatment response. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06392906
Study type Interventional
Source Mahidol University
Contact Janjira Petsuksiri, M.D.
Phone 66919966662
Email janjira.pet@mahidol.ac.th
Status Not yet recruiting
Phase Phase 3
Start date May 1, 2024
Completion date October 31, 2028

See also
  Status Clinical Trial Phase
Withdrawn NCT06087731 - Efficacy and Safety of Tocilizumab for TAO Phase 2
Recruiting NCT05110040 - Multi-model Image of Immunosuppressive Agents in TAO N/A
Recruiting NCT06112340 - A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) Phase 2/Phase 3
Recruiting NCT03107078 - Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial Phase 4
Recruiting NCT04548284 - Study of Therapeutic Value of Periorbital Injection of Glucocorticoid in Mild TAO Phase 3
Recruiting NCT03515863 - Natural History and Risk Factors of TAO
Recruiting NCT06226545 - A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease Phase 2
Completed NCT00150111 - Rituximab in the Treatment of Graves' Disease Phase 1/Phase 2
Completed NCT03110848 - Effects of Atorvastatin in Graves' Orbitopathy (GO) Phase 2
Recruiting NCT04662190 - Evaluation of the Efficacy and Safety of 3D Printing for Orbital Surgery. N/A
Active, not recruiting NCT05276063 - A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) Phase 2/Phase 3
Not yet recruiting NCT04919694 - Combination of Orbital Compression Surgery and Strabismus Surgery for Thyroid Associated Ophthalmopathy N/A
Recruiting NCT03131726 - Treatment of Graves´Ophthalmopathy With Simvastatin (GO-S) Phase 3
Completed NCT02766660 - Optic Disc, Macula, and Retinal Nerve Fiber Layer Measurements Obtained by OCT in Thyroid Associated Ophthalmopathy N/A
Active, not recruiting NCT06269393 - A Study of IBI311 in Subjects With Steroid-resistant, Thyroid Associated Ophthalmopathy Phase 3
Not yet recruiting NCT03098225 - A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy Phase 4
Recruiting NCT05112211 - Multi-model Image of Doxycycline in TAO N/A